Claude

What the Internet Knows

The Bottom Line from the Web

The web reveals a company in the middle of the most consequential transformation in its history – and the market is not buying it yet. The Burman family (Dabur promoters) completed a bruising 18-month takeover in February 2025, installed three family members on the board, pushed out scandal-tainted ex-chairperson Rashmi Saluja, and in February 2026 announced a demerger to separate insurance from financial services. Yet the stock fell 10% on the demerger news and has underperformed the Nifty by over 20 percentage points in two years. The single most important web finding: Care Health Insurance – REL's crown jewel – saw its operating profit collapse 86% in FY25 (from ₹356 Cr to ₹49 Cr) as claims grew faster than premiums, and H1 FY26 turned to a ₹70 Cr operating loss. This undermines the entire sum-of-parts thesis just as the company prepares for a potential Care Health IPO.

What Matters Most

1. Care Health Insurance Profitability Collapsing Despite Premium Growth

Care Health's GWP grew 21% to ₹8,318 Cr in FY25, but net profit fell 49% as claims surged 33% (₹3,074 Cr to ₹4,096 Cr). Operating profit cratered 86% from ₹356 Cr to ₹49 Cr. In H1 FY26, the situation worsened: the combined ratio crossed 1.0x, meaning the company is paying out more in claims and expenses than it earns from underwriting. PAT shrank to just ₹17 Cr vs ₹61 Cr a year earlier, propped up only by investment income of ₹222 Cr.

2. Demerger Announced Feb 2026 – Market Reacted with a 10% Sell-Off

REL's board approved demerging financial services (lending, broking, investment) into Religare Finvest Ltd (RFL), while retaining 63.2% stake in Care Health Insurance. RFL shares to be issued 1:1 to existing shareholders. Target listing: Q1 FY28. However, the stock fell 10% over seven consecutive sessions post-announcement. Analysts flagged persistent holding company discount and the complexity of regulatory approvals required (NCLT, SEBI, RBI, IRDAI).

3. RBI Lifted Corrective Action Plan on Religare Finvest – After 7 Years

On July 23, 2025, the RBI withdrew the CAP imposed on Religare Finvest since January 2018. The CAP had been triggered by irregularities during the Singh brothers' era, which caused accumulated losses of ₹2,270 Cr. The lifting followed RFL's completion of a ₹2,320 Cr one-time settlement with all lenders and changes in management/board composition under Burman control. This is a critical positive – RFL can now resume normal lending operations.

4. Burman Family Steadily Increasing Stake – Now 30.84%

The Burmans completed their ₹2,116 Cr open offer in February 2025 (only 0.07% shares tendered – tepid response). Post-offer, they held 25.16%. Since then, through warrant conversions at ₹235/share (19.86 lakh warrants converted December 2025) and open market purchases (50.38 lakh shares in March 2026), promoter stake has risen to 30.84%. With additional warrant conversion potential, it could exceed 34%.

5. ED Filed Chargesheet Against Ex-Chairperson Rashmi Saluja in ₹179.5 Cr ESOP Scam

In October 2025, the Enforcement Directorate filed a chargesheet calling Saluja the "principal architect" of a conspiracy involving ₹179.5 Cr in ESOP manipulation at Care Health Insurance. She allegedly received ESOPs representing 2.5% of Care Health's share capital. In January 2026, the Bombay High Court refused to quash the FIR and ECIR against her. The Supreme Court also rejected her plea to quash the Mumbai Police FIR. A proxy advisory firm (InGovern) has asked REL to update on recovery of ₹480 Cr from the ESOP clawback.

6. SEBI Imposed ₹60 Cr Fine on Singh Brothers for ₹2,473 Cr Fund Diversion

SEBI fined 10 entities including Malvinder and Shivinder Singh ₹60 Cr for diverting ₹2,473 Cr from RFL during FY2015-18. In January 2025, a Delhi court framed charges of conspiracy and cheating against both brothers. The SFIO investigation into REL and RFL affairs is ongoing since 2018. While these are legacy issues, they remain unresolved and continue to cast a shadow over the company's governance narrative.

7. Burman Family Board Takeover – Three Family Members + Jimeet Modi Inducted

In November 2025, REL's board inducted Anand Burman, Mohit Burman, and Aditya Burman (all Dabur family members) plus Samco Group founder Jimeet Modi. In July 2025, the non-executive chairman changed from Praveen Kumar Tripathi (tenure completed) to Malay Kumar Sinha. The Burmans also led a ₹1,500 Cr fund infusion into REL, contributing ₹750 Cr (half the total) via preferential allotment of 6.38 Cr warrants at ₹235 each.

8. Care Health Faces ₹140 Cr Tax Demand

In March 2026, Care Health Insurance received income tax demand orders totaling ₹140.20 Cr for AY 2023-24 and 2024-25. The company disputes the computation and expects the rectified demand to be approximately ₹96 Cr. Disallowances include provisions for IBNR, IBNER, outstanding claims, TDS compliance issues, and marketing expenses.

9. Care Health Is India's 2nd-Largest Standalone Health Insurer – But Competition Intensifying

The SAHI market nearly doubled from ₹63,700 Cr (FY21) to ₹1,18,688 Cr (FY25). Star Health's share halved from 60% to 32%. Care Health gained market share (260 bps over two years to Feb 2024), benefiting from Star's decline. However, Niva Bupa (+355 bps) and Aditya Birla Health (+270 bps) are growing faster. Care Health's unlisted shares trade at ₹118-121 as of April 2026, down from a 52-week high of ₹258 – a 53% decline suggesting IPO valuation expectations have been severely reset.

10. Religare Broking – Modest Market Share, CRISIL BBB/Stable Rating

CRISIL reaffirmed Religare Broking's 'CRISIL BBB/Stable/A3+' rating in February 2025 on ₹350 Cr bank facilities. The rating cited adequate capitalization and long track record but flagged "modest market share." In the broker rankings, Religare Broking is not among the top 10 by active clients, far behind leaders like Zerodha, Groww, and Angel One.

Recent News Timeline

What the Specialists Asked

Insider Spotlight

The insider picture tells a clear story: the Burman family is the only material insider accumulating shares, consistently converting warrants and buying in the open market. The two sets of former insiders – the Singh brothers and Rashmi Saluja – are both facing active criminal proceedings. The ₹480 Cr ESOP clawback from Saluja represents a potential asset recovery that could benefit Care Health's balance sheet, but the timeline and likelihood of recovery remain uncertain.

Industry Context

The Indian standalone health insurance market is growing rapidly (nearly doubling from FY21 to FY25), driven by rising healthcare awareness, medical inflation, and regulatory push for universal coverage. Star Health's dominance has eroded from 60% to 32%, creating a significant opportunity for Care Health, Niva Bupa, and Aditya Birla Health. The industry is projected to grow at 6.9% annually through 2030.

However, the critical challenge is profitability. Medical inflation is running ahead of premium repricing across the sector. Care Health's combined ratio crossing 1.0x in H1 FY26 is an industry-wide concern, not unique to Religare. The question for investors is whether the demerger and eventual Care Health IPO can unlock value in a market where the crown jewel's underwriting economics are deteriorating.